# EDGAR Filing Document

**Accession Number:** 0001768446
**File Stem:** 0001193125-26-092565
**Filing Date:** 2026-3
**Character Count:** 16034
**Document Hash:** f08477a6bf3e0ea3bf2e2d02c84446d9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-092565.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001193125-26-092565

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**EFFECTIVENESS DATE**: 20260305

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Climb Bio, Inc.
- **CENTRAL INDEX KEY:** 0001768446
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 832273741
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294029
- **FILM NUMBER:** 26724195

**BUSINESS ADDRESS:**
- **STREET 1:** 20 WILLIAM STREET
- **STREET 2:** SUITE 145
- **CITY:** WELLESLEY HILLS
- **STATE:** MA
- **ZIP:** 02481
- **BUSINESS PHONE:** 1-866-857-2596

**MAIL ADDRESS:**
- **STREET 1:** 20 WILLIAM STREET
- **STREET 2:** SUITE 145
- **CITY:** WELLESLEY HILLS
- **STATE:** MA
- **ZIP:** 02481

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Eliem Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20190219

**As filed with the U.S. Securities and Exchange Commission on March 5, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Climb Bio, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **83-2273741** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**20 William Street, Suite 145** 

**Wellesley Hills, Massachusetts 02481** 

**(866) 857-2596** 

**(Address of principal executive offices) (Zip code)** 

**Climb Bio, Inc. 2021 Equity Incentive Plan** 

**Climb Bio, Inc. 2021 Employee Stock Purchase Plan** 

**Climb Bio, Inc. 2025 Inducement Plan, as amended** 

**(Full title of the plan)** 

**Aoife Brennan, M.B., Ch.B.** 

**President and Chief Executive Officer** 

**Climb Bio, Inc.** 

**20 William Street, Suite 145** 

**Wellesley Hills, Massachusetts 02481** 

**(866) 857-2596** 

**(Name and address of agent for service) (Telephone number, including area code, of agent for service)** 

***Copy to:***

**Christopher D. Barnstable-Brown** 

**Scott N. Lunin** 

**Wilmer Cutler Pickering Hale and Dorr LLP** 

**7 World Trade Center** 

**250 Greenwich Street** 

**New York, New York 10007** 

**(212) 230-8800** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

This Registration Statement on Form S-8, relating to an aggregate of (a) 2,388,316 shares of common stock, par value $0.0001 per share ("Common Stock"), issuable under the 2021 Equity Incentive Plan (the "2021 Plan") of Climb Bio, Inc. (the "Registrant"), (b) 477,663 shares of Common Stock issuable under the 2021 Employee Stock Purchase Plan (the "ESPP") of the Registrant and (c) 750,000 shares of Common Stock issuable under the 2025 Inducement Plan, as amended (the "2025 Inducement Plan"), of the Registrant, is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of the Registration Statement on [Form S-8](http://www.sec.gov/Archives/edgar/data/1768446/000119312525070421/d853209ds8.htm), File No. 333-286303, filed by the Registrant with the Securities and Exchange Commission on April 1, 2025 relating to the 2021 Plan, the ESPP and the 2025 Inducement Plan, except to the extent amended or superseded by the contents hereof.

**Item 8. Exhibits.** 

The following exhibits are incorporated herein by reference:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit<br>Number** | **Description** | **<br>Form** | **File<br>Number** | **Exhibit** | **Filing Date** |
| 4.1 | [Amended and Restated Certificate of Incorporation, as amended, of the Registrant.](http://www.sec.gov/Archives/edgar/data/1768446/000095017024125294/clym-ex3_1.htm) | 10-Q | 001-40708 | 3.1 | November<br> 12, 2024 |
| 4.2 | [Amended and Restated Bylaws of the Registrant.](http://www.sec.gov/Archives/edgar/data/1768446/000119312524231167/d888487dex32.htm) | 8-K | 001-40708 | 3.2 | October<br> 2, 2024 |
| 4.3 | [Form of common stock certificate of the Registrant.](http://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-ex4_1.htm) | 10-K | 001-40708 | 4.1 | March<br> 25, 2025 |
| 5.1\* | [Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant.](d124511dex51.htm) |  |  |  |  |
| 23.1\* | [Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.](d124511dex231.htm) |  |  |  |  |
| 23.2\* | [Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1).](d124511dex51.htm) |  |  |  |  |
| 24.1\* | [Power of Attorney (included on the signature page of this registration statement).](#sig) |  |  |  |  |
| 99.1 | [2021 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-ex10_1.htm) | 10-K | 001-40708 | 10.1 | March<br> 25, 2025 |
| 99.2 | [2021 Employee Stock Purchase Plan.](http://www.sec.gov/Archives/edgar/data/1768446/000095017025044350/clym-ex10_4.htm) | 10-K | 001-40708 | 10.4 | March<br> 25, 2025 |
| 99.3 | [2025 Inducement Plan, as amended.](http://www.sec.gov/Archives/edgar/data/1768446/000119312525268086/clym-ex10_1.htm) | 10-Q | 001-40708 | 10.1 | November<br> 6, 2025 |
| 107\* | [Filing Fee Table.](d124511dexfilingfees.htm) |  |  |  |  |

---

\* Filed herewith

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wellesley Hills, Commonwealth of Massachusetts, on this 5th day of March, 2026.

---

| | |
|:---|:---|
| **CLIMB BIO, INC.** | **CLIMB BIO, INC.** |
| By: | /s/ Aoife Brennan |
|  | **Aoife Brennan, M.B., Ch.B.** |
|  | **President and Chief Executive Officer** |

---

**POWER OF ATTORNEY AND SIGNATURES** 

We, the undersigned officers and directors of Climb Bio, Inc., hereby severally constitute and appoint Aoife Brennan, M.B., Ch.B., Cindy J. Driscoll and Chandra Adams, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Climb Bio, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Aoife Brennan | &nbsp;&nbsp;&nbsp;&nbsp; President, Chief Executive Officer and Director | &nbsp;&nbsp;&nbsp;&nbsp; March 5, 2026 |
| **Aoife Brennan, M.B., Ch.B.** | &nbsp;&nbsp;&nbsp;&nbsp; *(Principal Executive Officer)* |  |
| /s/ Susan Altschuller | &nbsp;&nbsp;&nbsp;&nbsp; Chief Financial Officer | &nbsp;&nbsp;&nbsp;&nbsp; March 5, 2026 |
| **Susan Altschuller, Ph.D., MBA** | &nbsp;&nbsp;&nbsp;&nbsp; *(Principal Financial Officer)* |  |
| /s/ Cindy J. Driscoll | &nbsp;&nbsp;&nbsp;&nbsp; Senior Vice President, Finance | &nbsp;&nbsp;&nbsp;&nbsp; March 5, 2026 |
| **Cindy J. Driscoll, MBA** | &nbsp;&nbsp;&nbsp;&nbsp; *(Principal Accounting Officer)* |  |
| /s/ Douglas E. Williams | &nbsp;&nbsp;&nbsp;&nbsp; Director | &nbsp;&nbsp;&nbsp;&nbsp; March 5, 2026 |
| **Douglas E. Williams, Ph.D.** | &nbsp;&nbsp;&nbsp;&nbsp;*(Chairman)* |  |
| /s/ Alexander Cumbo | &nbsp;&nbsp;&nbsp;&nbsp; Director | &nbsp;&nbsp;&nbsp;&nbsp; March 5, 2026 |
| **Alexander Cumbo** |  |  |
| /s/ Kimberlee C. Drapkin | &nbsp;&nbsp;&nbsp;&nbsp; Director | &nbsp;&nbsp;&nbsp;&nbsp; March 5, 2026 |
| **Kimberlee C. Drapkin, CPA** |  |  |
| /s/ Judith Dunn | &nbsp;&nbsp;&nbsp;&nbsp; Director | &nbsp;&nbsp;&nbsp;&nbsp; March 5, 2026 |
| **Judith Dunn, Ph.D.** |  |  |
| /s/ Andrew Levin | &nbsp;&nbsp;&nbsp;&nbsp; Director | &nbsp;&nbsp;&nbsp;&nbsp; March 5, 2026 |
| **Andrew Levin, M.D., Ph.D.** |  |  |
| /s/ Stephen Thomas | &nbsp;&nbsp;&nbsp;&nbsp; Director | &nbsp;&nbsp;&nbsp;&nbsp; March 5, 2026 |
| **Stephen Thomas, Ph.D.** |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g124511dsp6.jpg)

+1 212 230 8800 (t)

+1 212 230 8888 (f)

wilmerhale.com

March 5, 2026

Climb Bio, Inc.

20 William Street, Suite 145

Wellesley Hills, Massachusetts 02481

Re: 2021 Equity Incentive Plan

2021 Employee Stock Purchase Plan

2025 Inducement Plan, as amended

Ladies and Gentlemen:

We have assisted in the preparation of a Registration Statement on Form S-8 (the "Registration Statement") to be filed with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), relating to an aggregate of 3,615,979 shares of common stock, $0.0001 par value per share (the "Shares"), of Climb Bio, Inc., a Delaware corporation (the "Company"), issuable under the Company's 2021 Equity Incentive Plan, 2021 Employee Stock Purchase Plan and 2025 Inducement Plan, as amended (collectively, the "Plans").

We have examined the Certificate of Incorporation and By-Laws of the Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the board of directors and stockholders of the Company, the Registration Statement, the Plans and such other documents relating to the Company as we have deemed material for the purposes of this opinion.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.

We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Plans, to register and qualify the Shares for sale under all applicable state securities or "blue sky" laws.

We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.

It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Plans, as applicable, the Shares will be validly issued, fully paid and nonassessable.

![LOGO](g124511dsp6a.jpg)

------

---

| | |
|:---|:---|
| Climb Bio, Inc.<br> March 5, 2026<br> Page 2 | ![LOGO](g124511dsp6.jpg) |

---

We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

---

| |
|:---|
| Very truly yours, |
| /s/ Wilmer Cutler Pickering Hale and Dorr LLP |
| WILMER CUTLER PICKERING HALE AND DORR LLP |

---

## Exhibit 23.1

**Exhibit 23.1** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Climb Bio, Inc. of our reported date March 5, 2026 relating to the financial statements, which appear in Climb Bio, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025.

<u>/s/ PricewaterhouseCoopers LLP</u> 

Seattle, Washington

March 5, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Climb Bio, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.0001 par value per share | Other | 3615979 | $6.97 | $25203374.00 | 0.0001381 | $3481.00 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $25203374.00  |  | $3481.00  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $3481.00  |

---

 **Offering Note** <br>

<sup>1</sup> (1) In accordance with Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. (2) Consists of (i) 2,388,316 additional shares issuable under the 2021 Equity Incentive Plan and (ii) 477,663 additional shares issuable under the 2021 Employee Stock Purchase Plan and (iii) 750,000 additional shares issuable under the 2025 Inducement Plan, as amended. (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act and based upon the average of the high and low prices of the registrant's common stock as reported on the Nasdaq Global Market on March 2, 2026.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---